Targeted Protein Modulators – Cellular to ADME to PK/PD models and correlations
Presenting the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool SynTAC-ERD, an Estrogen Receptor (ER) degrader.
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
Transforming Supply Chain risks into a competitive advantage in the CRO-CDMO space-The Syngene story
Learn how Syngene built a biopharma supply chain that is fast, resilient, and future-proof and, in the process, turned supply chain risks into a competitive advantage.
Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
How Syngene’s safety tox package helped Cytopeutics to advance its cell therapy drug to the Clinic
Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.
Intensified Biomanufacturing
Learn how Syngene is achieving three to four-fold higher titers of mAbs using its Intensified Fed-Batch process
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
Publication: mAbs
Minimizing environmental footprint the Syngene way
How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.
Enabling early assessment of drug targets to maximize clinical and commercial success
Comprehensive diligence around a target at the start of a discovery program can make the difference between success and failure. Learn how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.
Integrated or Standalone: How the industry thinks about drug development outsourcing
Read this white paper to gain insights about perceptions around integrated and standalone outsourcing. The white paper is based on surveys conducted across emerging biopharma, mid-size and large pharma in North America, Europe and other regions.